Veru advances oral sabizabulin toward Phase 2 in daraxonrasib-resistant pancreatic cancerSep 8Clinical readoutdaraxonrasibRevolution Medicines, Inc.
Revolution Medicines registers Phase 3 RASolute 309 in KRAS G12D pancreatic cancerSep 8Trial updatedaraxonrasibRevolution Medicines, Inc.
Johns Hopkins registers Phase 2 trial of Revolution Medicines' daraxonrasib in biliary tract cancerAug 28Trial updatedaraxonrasibRevolution Medicines, Inc.
Tango reports Phase 1/2 pancreatic cancer data, eyes Phase 3 as it posts Q2 2026 resultsAug 11Quarterly updateTango Therapeutics, Inc.
Tango Therapeutics files new $400 million at-the-market equity offering with Leerink PartnersAug 11FinancingTango Therapeutics, Inc.
Synnovation registers Phase 1 trial of SNV1521 with Revolution Medicines' daraxonrasibAug 10Trial updatedaraxonrasibRevolution Medicines, Inc.
Royalty Pharma raises 2026 guidance after 14% Royalty Receipts growth in Q2Aug 5Quarterly updateRoyalty Pharma plc
Revolution Medicines advances daraxonrasib NDA and reports new lung cancer combination dataAug 5Quarterly updatedaraxonrasibRevolution Medicines, Inc.
Nuvectis reports Q2 2026 results as ciprocopan wins first China approvalAug 4Quarterly updateNuvectis Pharma, Inc.
Sign inSign in